셀트리온
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | KRW 1.9tn | KRW 2.3tn | KRW 2.2tn | KRW 3.6tn | KRW 4.2tn | KRW |
| Operating income | KRW 756.9bn | KRW 647.2bn | KRW 651.5bn | KRW 492.0bn | KRW 1.2tn | KRW |
| Net income | KRW 579.5bn | KRW 537.8bn | KRW 535.6bn | KRW 422.7bn | KRW 1.0tn | KRW |
| Total equity | KRW 3.9tn | KRW 4.1tn | KRW 17.0tn | KRW 17.4tn | KRW 17.2tn | KRW |
| Total liabilities | KRW 1.6tn | KRW 1.6tn | KRW 2.8tn | KRW 3.5tn | KRW 5.0tn | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 41.45 | 39.07 | 16.44 | 19.93 | 28.95 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Show raw values
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | 1,911,601,263,030 | 2,283,967,480,394 | 2,176,431,531,380 | 3,557,303,554,371 | 4,162,495,108,881 | KRW |
| Operating income | 756,857,107,226 | 647,198,174,586 | 651,481,422,157 | 492,015,534,847 | 1,168,471,345,595 | KRW |
| Net income | 579,464,583,818 | 537,835,568,483 | 535,647,963,959 | 422,691,724,154 | 1,029,613,370,428 | KRW |
| Total equity | 3,917,237,794,242 | 4,139,360,000,764 | 16,980,683,406,963 | 17,439,141,579,252 | 17,208,474,471,870 | KRW |
| Total liabilities | 1,623,747,845,677 | 1,617,448,041,462 | 2,791,739,989,934 | 3,475,160,069,015 | 4,982,370,370,686 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준) | 41.45 | 39.07 | 16.44 | 19.93 | 28.95 | % |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 179,700
- 80%
- 176,002.22 ~ 183,789.43
- 90%
- 174,437.13 ~ 186,186.48
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-12Filing title as filed연결재무제표기준영업(잠정)실적(공정공시) original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed주요사항보고서(자기주식취득결정) original ↗Source: dart_disclosure
- 2026-09-23Filing title as filed투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인) original ↗Source: dart_disclosure
- 2026-09-23Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-21Filing title as filed투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2)) original ↗Source: dart_disclosure
- 2026-09-16Filing title as filed주식소각결정 original ↗Source: dart_disclosure
- 2026-09-16Filing title as filed자기주식취득결과보고서 original ↗Source: dart_disclosure
- 2026-09-07Filing title as filed투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인) original ↗Source: dart_disclosure
- 2026-09-07Filing title as filed투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인) original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed수시공시의무관련사항(공정공시) original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed주요사항보고서(자기주식취득결정) original ↗Source: dart_disclosure
- 2026-08-28Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-28Filing title as filed대규모기업집단현황공시[분기별공시(개별회사용)] original ↗Source: dart_disclosure
- 2026-08-25Filing title as filed풍문또는보도에대한해명(미확정) original ↗Source: dart_disclosure
- 2026-08-24Filing title as filed투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품목허가 신청) original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 original ↗Source: dart_disclosure
- 2026-08-03Filing title as filed투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청) original ↗Source: dart_disclosure
- 2026-08-03Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…